Orders by weight:
- Super immunodeficient NOG mouse expressing human IL-6 cytokine
- Enhanced expansion of human monocytes following human HSC engraftment
- May be useful for study of tumor-infiltrating macrophages
- May be suitable host for hIL-6 dependent multiple myeloma (MM) patient derived xenograft (PDX) and tumor samples.
- Applications in research involving cancer, immunology, regenerative medicine and human immune system engraftment
Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
What our customers say:“Experimental Pharmacology & Oncology (EPO) GmbH uses 1st and 2nd generation NOG mice provided by Taconic for its preclinical oncology service. These mice are included in novel concepts for the development of personalized treatment options and especially suited for humanization strategies. We are very satisfied with the quality of mice, the reliability of shipment and the high level of scientific support. Further, we very much appreciate the competent and always friendly communication.”
Experimental Pharmacology & Oncology (EPO) GmbH
Origin: The CIEA NOG mouse® was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Portions of exons 7 and 8 were replaced with a neo cassette. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The CIEA NOG mouse® was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The linearized hIL-6 transgene was injected into zygotes from NOD/Shi-IL2rg females x NOD/Shi-IL2rg males. The transgenic hIL-6 NOD/Shi-IL2rg mouse was crossed on to the NOG background to introduce the Prkdc scid mutation. The mice were backcrossed onto the NOG background three times. Taconic received stock in 2014, and the line was derived through embryo transfer.
Availability: Available now*
*Please note that advanced order placement is encouraged for male mice. Ordering 4 or more weeks prior to the desired shipping date is recommended when requesting males older than 3-weeks of age.
Hanazawa A, Ito R, Katano I, Kawai K, Goto M, Suemizu H, Kawakami Y, Ito M, Takahashi T. (2018) Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice. Front Immunol 9:152